Edition:
India

Catabasis Pharmaceuticals Inc (CATB.OQ)

CATB.OQ on NASDAQ Stock Exchange Global Market

0.87USD
20 Jun 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$0.87
Open
--
Day's High
--
Day's Low
--
Volume
5,000
Avg. Vol
155,034
52-wk High
$3.78
52-wk Low
$0.86

Chart for

About

Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer... (more)

Overall

Beta: --
Market Cap(Mil.): $55.98
Shares Outstanding(Mil.): 22.48
Dividend: --
Yield (%): --

Financials

BRIEF-Catabasis Pharmaceuticals Reports Q1 Loss Per Share $0.29

* CATABASIS PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND REVIEWS BUSINESS PROGRESS

10 May 2018

BRIEF-Catabasis Pharmaceuticals Presents New Edasalonexent Data

* CATABASIS PHARMACEUTICALS PRESENTS NEW EDASALONEXENT DATA SHOWING SIGNIFICANTLY SLOWED DUCHENNE MUSCULAR DYSTROPHY DISEASE PROGRESSION AS MEASURED BY MRI THROUGH ONE YEAR OF TREATMENT

26 Apr 2018

BRIEF-Catabasis Pharma Aligns Resources To Focus On Lead Program Edasalonexent

* CATABASIS PHARMACEUTICALS ALIGNS RESOURCES TO FOCUS ON LEAD PROGRAM EDASALONEXENT FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

18 Apr 2018

BRIEF-Clarus Lifesciences II Lp Reports A 6.92 Pct Stake In Catabasis Pharmaceuticals As Of March 22

* CLARUS LIFESCIENCES II LP REPORTS A 6.92 PCT STAKE IN CATABASIS PHARMACEUTICALS INC AS OF MARCH 22 - SEC FILING

05 Apr 2018

BRIEF-Catabasis Pharmaceuticals Reports Q4 Loss Per Share $0.24

* CATABASIS PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND REVIEWS BUSINESS PROGRESS

16 Mar 2018

BRIEF-Corriente Advisors Reports 7.3 Pct Passive Stake In Catabasis Pharmaceuticals‍​

* CORRIENTE ADVISORS LLC REPORTS 7.3 PERCENT PASSIVE STAKE IN CATABASIS PHARMACEUTICALS INC AS OF FEBRUARY 16, 2018 - SEC FILING‍​ Source text : (http://bit.ly/2CDqdMi) Further company coverage:

23 Feb 2018

BRIEF-Catabasis Reports Edasalonexent Preserved Muscle Function And Substantially Slowed Duchenne Muscular Dystrophy Disease Progression

* CATABASIS PHARMACEUTICALS REPORTS EDASALONEXENT PRESERVED MUSCLE FUNCTION AND SUBSTANTIALLY SLOWED DUCHENNE MUSCULAR DYSTROPHY DISEASE PROGRESSION THROUGH MORE THAN ONE YEAR OF TREATMENT

13 Feb 2018

Earnings vs. Estimates